News
Non-Vitamin K Antagonist Oral Anticoagulants vs Warfarin in NVAF Patients
Findings may help with decision-making in this high-risk patient population.
Your search for oral corticosteroids returned 18 results
ATS 2021, News
Oral Corticosteroid Dose Management With Impaired Adrenal Function Evaluated
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
AAAAI 2021, News
Benralizumab May Reduce or Eliminate Oral Corticosteroid Use in Severe Asthma
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
News
Drug-Induced Immunosuppression Examined in US Adults
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
Drugs in the Pipeline, News
FDA Grants Fast Track Designation to Orismilast for Atopic Dermatitis
The FDA's Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
CHEST 2021, News
Tezepelumab Improves Lung Function in Severe, Uncontrolled Asthma
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
CHEST 2021, News
Dupilumab Improves Severe Asthma Outcomes, Regardless of Baseline OCS Dose
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
News
Saphnelo Approved for Systemic Lupus Erythematosus
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
News
Tacrolimus May Be an Alternative for First-Line Lupus Nephritis Therapy
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
News
Rinvoq Approved for Moderately to Severely Active Ulcerative Colitis
The approval was based on data from two phase 3 induction studies and one phase 3 maintenance study.
